a year ago

IsomAb Raises £7.5 Million to Develop Treatment for Diabetic Peripheral Arterial Disease

  • IsomAb, a University of Nottingham spin-out, has raised £7.5 million to develop a new treatment for diabetic peripheral arterial disease (PAD)

  • The company's lead program targets VEGF-A165b, a protein that blocks the angiogenesis process in diabetics, with the goal of improving blood flow in patients with PAD

  • The funding round was led by Broadview Ventures and backed by MEIF Proof of Concept & Early Stage Fund, Mercia Ventures, Mercia's EIS funds, and existing investor SCVC

  • The funds will be used to further develop the treatment and prepare for clinical trials.

      • ProblemHealthcare

      "Diabetic patients with peripheral arterial disease (PAD) often suffer from blocked arteries in their legs and feet, leading to a lack of blood flow and an inability to develop new blood vessels. This lack of circulation causes ulcers and irreversible tissue damage, potentially leading to amputation."

      Solution

      "IsomAb has developed an antibody that inhibits the effects of a protein called VEGF-A165b, which blocks the angiogenesis process in diabetics. This antibody allows new blood vessels to be created, potentially alleviating the symptoms of PAD and preventing amputation."

      Covered on